Tebra Launches AI Note Assist, Reducing Clinical Documentation Time by 50% for Independent Practices
'My notes used to take 30 to 60 minutes because they would be so detailed. With the Tebra AI Note Assist, each of my notes today took not even five minutes,' said Angela Davis-Taylor, FNP-C, INHC, of Daisy Family Health Care.
Share
This launch addresses a critical challenge: Physicians spend an average of 15.5 hours per week on paperwork and administrative tasks, contributing to widespread burnout that affects nearly 50% of practicing doctors. AI Note Assist offers independent practices an immediate solution to reclaim valuable time for patient care.
Seamlessly embedded into Tebra's EHR, AI Note Assist listens during patient visits and automatically generates structured, editable clinical notes. Built with enterprise-grade security and clinically tested for accuracy, this underwent extensive validation with practicing providers to ensure reliability in real-world settings.
This tool empowers providers to complete documentation twice as fast, with early adopters reporting a 50% reduction in note-taking time.
'My notes used to take 30 to 60 minutes because they would be so detailed. With the Tebra AI Note Assist, each of my notes today took not even five minutes,' said Angela Davis-Taylor, FNP-C, INHC, of Daisy Family Health Care.
'What I like about the AI Note Assist is I can do small talk with my patient, and the AI can pick up the parts of the conversation that matter the most, and filter out what's irrelevant. So I feel like I can be myself in the room, which is comforting,' added Erica Cheshire, ANP-BC, of Beaumont WELLness for Women.
AI Note Assist supports multiple clinical documentation formats — including SOAP, Therapy Initial and Progress, and Psychiatric notes — and intelligently suggests ICD-10 codes based on conversation details. Providers maintain full control with the ability to review, edit, and approve notes before finalizing, ensuring clinical accuracy and completeness.
"The launch of AI Note Assist is a significant milestone in our mission to empower independent practices," said Kyle Ryan, Chief Product and Technology Officer at Tebra. "Our own research shows that 82% of independent providers believe more patient time is their key competitive advantage over large healthcare networks. We're delivering powerful, affordable AI tools that help providers reclaim that advantage by working efficiently, reducing burnout, and focusing on what matters most — delivering exceptional patient care. We expect AI Note Assist to save our customers thousands of administrative hours while significantly improving provider satisfaction."
The solution is available to Tebra customers immediately through their existing platform, requiring no additional hardware or software installations. This addresses a critical need, as Tebra research shows 80% of providers experiencing decreased job satisfaction directly link it to insufficient patient interaction time. Independent practices can begin reducing documentation time today while maintaining clinical quality and compliance requirements they require.
For more information or to schedule a demonstration, visit www.tebra.com/ai
About Tebra
Tebra is the only all-in-one EHR+ platform built exclusively for independent healthcare practices. Designed to replace the clunky, fragmented tools built for corporate systems, Tebra connects EHR, billing, automation, telehealth, and marketing — so providers can spend less time on admin and more time with patients. More than 42,000 private practices trust Tebra to streamline operations, increase revenue, and reduce burnout — helping clinicians leave work on time and rediscover their purpose. Learn more at www.tebra.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
13 hours ago
- Time Business News
Healthcare Data Analyst Jobs with Visa Sponsorship 2025
The healthcare industry has transformed drastically in the last decade. With hospitals, research institutes, and pharmaceutical companies depending heavily on digital records, the role of Healthcare Data Analyst Jobs with Visa Sponsorship has never been more important. A healthcare data analyst helps organizations make sense of the massive amounts of medical data generated every single day. For job seekers outside developed countries, this trend has created a golden opportunity. Many employers in the United States, the United Kingdom, Canada, Australia, and the Middle East now actively hire international professionals by offering visa sponsorship. This not only helps fill the shortage of talent but also opens pathways for foreign workers to build stable careers abroad. Apply now for Healthcare Data Analyst Jobs with Visa Sponsorship 2025: Best to Apply Now In this detailed guide, we'll explore everything you need to know about Healthcare Data Analyst Jobs with Visa Sponsorship — from responsibilities and required skills to visa processes, top countries, salary ranges, application strategies, and frequently asked questions. By the end, you'll have a clear roadmap to pursue a healthcare data analyst career with visa sponsorship opportunities. A Healthcare Data Analyst is a professional who collects, processes, and interprets healthcare-related data to improve decision-making in hospitals, research centers, and insurance companies. Their work revolves around transforming raw medical data into actionable insights. Gathering data from electronic health records (EHRs), clinical trials, and patient surveys Using tools like SQL, Python, or R to analyze datasets Identifying patterns that can improve patient outcomes Creating dashboards with tools like Tableau or Power BI for decision-makers Supporting compliance with healthcare regulations such as HIPAA (USA) or GDPR (Europe) Tracking healthcare costs and suggesting efficiency improvements Healthcare data analysts combine technical expertise with healthcare knowledge, making them essential to modern medical systems. The demand for Healthcare Data Analyst Jobs with Visa Sponsorship is growing worldwide. Several factors contribute to this surge: Digital Transformation in Healthcare Hospitals and clinics are moving away from paper records to electronic health records (EHRs). This shift creates a massive need for skilled professionals who can manage and analyze data. Global Healthcare Challenges The COVID-19 pandemic highlighted the importance of data analytics in public health. Governments and hospitals rely on accurate data to track disease spread, vaccine effectiveness, and patient outcomes. AI and Predictive Analytics Organizations are adopting AI and machine learning to predict patient risks and improve preventive care. Skilled healthcare data analysts are needed to train and manage these models. Talent Shortage in Developed Countries Countries like the US, UK, and Canada do not have enough local data professionals. This opens doors for international candidates who can work under visa sponsorship programs. Visa sponsorship means an employer supports a foreign worker's visa application, allowing them to live and work legally in another country. In the context of Healthcare Data Analyst Jobs with Visa Sponsorship, it works like this: The employer issues a formal job offer. The employer files documents with immigration authorities. The visa is processed, enabling the candidate to relocate and work. In some cases, sponsorship also covers visa fees and relocation support. Popular visa categories for healthcare data analysts include: USA: H-1B Visa (Specialty Occupations) H-1B Visa (Specialty Occupations) UK: Skilled Worker Visa (formerly Tier 2) Skilled Worker Visa (formerly Tier 2) Canada: Global Talent Stream or Express Entry Global Talent Stream or Express Entry Australia: Employer Sponsored Visa (482) Employer Sponsored Visa (482) UAE / Gulf States: Employer-based work visa The US is the largest employer of healthcare data analysts. Visa: H-1B visa sponsorship is common. H-1B visa sponsorship is common. Salary Range: $70,000 – $120,000 annually $70,000 – $120,000 annually Top Employers: UnitedHealth Group, Mayo Clinic, CVS Health, Kaiser Permanente, biotech firms UnitedHealth Group, Mayo Clinic, CVS Health, Kaiser Permanente, biotech firms Skills Needed: SQL, Python, R, Tableau, Epic Systems (EHR), HIPAA compliance The UK National Health Service (NHS) and private healthcare organizations actively hire international data analysts. Visa: Skilled Worker Visa sponsorship Skilled Worker Visa sponsorship Salary Range: £30,000 – £55,000 per year £30,000 – £55,000 per year Top Employers: NHS Trusts, Bupa, Deloitte Healthcare NHS Trusts, Bupa, Deloitte Healthcare Skills Needed: Power BI, statistics, predictive modeling, GDPR compliance Canada's healthcare system faces a shortage of skilled professionals. Visa: Express Entry, Global Talent Stream, Provincial Nominee Programs Express Entry, Global Talent Stream, Provincial Nominee Programs Salary Range: CAD $60,000 – $95,000 annually CAD $60,000 – $95,000 annually Top Employers: Canadian Institute for Health Information, provincial health services, pharma companies Australia is rapidly digitizing its healthcare system. Visa: Employer Sponsored Visa (482), Skilled Independent Visa (189) Employer Sponsored Visa (482), Skilled Independent Visa (189) Salary Range: AUD $70,000 – $110,000 annually AUD $70,000 – $110,000 annually Employers: Public hospitals, research institutes, health insurance providers The Gulf region is investing heavily in smart hospitals. Visa: Employer-sponsored work visa Employer-sponsored work visa Salary Range: $50,000 – $90,000 tax-free $50,000 – $90,000 tax-free Employers: Dubai Health Authority, Ministry of Health, private hospitals To secure Healthcare Data Analyst Jobs with Visa Sponsorship, candidates must meet certain requirements: Bachelor's degree in Data Science, Statistics, Computer Science, or Healthcare Informatics Master's degree preferred for advanced roles Programming languages: SQL, Python, R Data visualization: Tableau, Power BI Statistics and predictive modeling Knowledge of EHR systems (Epic, Cerner, Meditech) Critical thinking and problem solving Communication and teamwork Understanding of healthcare regulations Job Portals Indeed, Glassdoor, LinkedIn (filter for 'visa sponsorship') Specialized sites like NHS Jobs (UK), Healthcare IT Central Networking Join LinkedIn groups and healthcare data conferences Connect with recruiters specializing in healthcare analytics Employer Websites Apply directly through hospital, insurance, and pharmaceutical company websites Optimize Your Resume Highlight both technical and healthcare skills Mention willingness to relocate and visa sponsorship interest Earn Certifications : Google Data Analytics, SAS, Tableau Specialist : Google Data Analytics, SAS, Tableau Specialist Build a Portfolio : Publish healthcare data projects on GitHub or Kaggle : Publish healthcare data projects on GitHub or Kaggle Target Sponsoring Employers : Check government lists of licensed visa sponsors : Check government lists of licensed visa sponsors Prepare for Interviews : Expect technical and scenario-based healthcare questions : Expect technical and scenario-based healthcare questions Stay Flexible: Be open to relocating to smaller cities where demand is high Employer files a petition (Form I-129) USCIS approves petition Candidate applies at US consulate Visa granted → relocation Employer provides Certificate of Sponsorship (CoS) Candidate applies online with required documents Visa approved → relocation Employer gets LMIA exemption Candidate applies for work permit Work visa issued within weeks Employer nominates candidate Candidate applies for visa Visa granted → relocation High competition for limited visa (especially US H-1B) Meeting country-specific eligibility criteria Adjusting to new healthcare regulations Need for strong communication skills in English 1. What is the average salary for Healthcare Data Analyst Jobs with Visa Sponsorship? Salaries range from $60,000 to $120,000 annually depending on country and experience. 2. Do US employers sponsor visas for healthcare data analysts? Yes, many US hospitals and healthcare firms sponsor H-1B visas. 3. Can fresh graduates get healthcare data analyst jobs abroad with visa sponsorship? It's challenging but possible if you have certifications, strong technical skills, and relevant internships. 4. What skills do employers look for the most? SQL, Python, R, Tableau/Power BI, statistics, and healthcare regulation knowledge. 5. Is the UK offering visa sponsorship for healthcare data analysts? Yes, under the Skilled Worker visa program. 6. Which country is easiest for visa sponsorship? Canada and the UK are considered easier compared to the US. 7. Do healthcare data analyst jobs lead to permanent residency? Yes, many visa sponsorship programs eventually allow PR applications. 8. Can remote jobs include visa sponsorship? Mostly no — visa sponsorship usually requires physical relocation. 9. What industries hire healthcare data analysts the most? Hospitals, pharmaceutical companies, insurance firms, and government health departments. 10. How can I find verified visa sponsoring employers? Check official government lists of licensed sponsors (e.g., UK Home Office, US Department of Labor). The global demand for Healthcare Data Analyst Jobs with Visa Sponsorship is only going to increase. As healthcare becomes more data-driven, professionals with the right mix of technical expertise and healthcare knowledge will find abundant opportunities abroad. Whether you aim for the US, UK, Canada, Australia, or the Middle East, building your skills, optimizing your resume, and targeting visa-sponsoring employers will give you the best chance of success. With the right preparation, you can not only secure a high-paying job but also open the door to long-term residency and career growth in the healthcare industry. TIME BUSINESS NEWS
Business Insider
a day ago
- Business Insider
Lockheed Martin awarded $110.9M Navy contract modification
Lockheed Martin (LMT) was awarded a $110.9M cost-plus-fixed fee modification to a previously awarded contract for Trident II missile production and deployed systems support. Work is expected to be completed Sept. 30, 2029. The maximum dollar value of the contract action is $110.9M. This contract is being awarded to the contractor on a sole source basis under 10 U.S. Code 3204 and was previously synopsized on the Systems for Award Management website, with one proposal received. Strategic Systems Programs, Washington, D.C., is the contracting activity. The information contained in the announcement is unclassified. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Associated Press
a day ago
- Associated Press
Xebra Brands Announces Share Consolidation and Provides Update on MCTO
VANCOUVER, BC / ACCESS Newswire / August 15, 2025 / Xebra Brands Ltd. ('Xebra') (CSE:XBRA)(FSE:9YC), a international cannabis company, announces that it intends to consolidate its issued and outstanding common shares (the 'Common Shares') on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the 'Consolidation'). As of the date hereof, there are 84,144,855 Common Shares issued and outstanding and on a post-Consolidation basis, the Company shall have approximately 8,414,486 Common Shares issued and outstanding. No fractional Common Shares will be issued as a result of the Consolidation. Any fractional interest in Common Shares that is less than 0.5 of a Common Share resulting from the Consolidation will be rounded down to the nearest whole Common Share, and any fractional interest in Common Shares that is equal to or greater than 0.5 of a Common Share will be rounded up to the nearest whole Common Share. The Common Shares will be expected begin trading on a consolidated basis and with a new CUSIP number on or around August 28, 2025, subject to regulatory approvals, including the approval of the CSE. Pursuant to the Business Corporations Act (British Columbia) and the articles of the Company, shareholder approval of Consolidation is not required. Shareholders of the Company who hold their shares through a securities broker or dealer, bank or trust company will not be required to take any measures with respect to the Consolidation. Xebra's transfer agent, Computershare Investor Services Inc. ('Computershare'), will mail a letter of transmittal to all registered shareholders of Xebra that will contain instructions for exchanging their pre-Consolidation Common Shares for post-Consolidation Common Shares. Registered shareholders will be required to return their certificates representing pre-Consolidation Common Shares and a completed letter of transmittal to Computershare. Any registered shareholder who submits a duly completed letter of transmittal to Computershare along with pre-Consolidation share certificate will receive in return a post-Consolidation share certificate or Direct Registration System Advice. Xebra's outstanding warrants and options will be adjusted on the same basis (10 to 1) as the Common Shares, with proportionate adjustments being made to exercise prices. The Company is also providing an update to its previously disclosed management cease trade order ('MCTO'), announced on July 2, 2025, in respect of the audited annual financial statements and corresponding management's discussion and analysis for the year ended February 28, 2025, including the CEO and CFO certifications (collectively, the 'Annual Financial Filings') that were not filed by the required filing deadline of June 30, 2025 (the 'Filing Deadline'). As previously disclosed, the Annual Financial Filings were not filed by the Filing Deadline because there have been certain liquidity constraints and delays associated with recent changes of management. The Company is working expeditiously to address the liquidity constraints and implement management changes necessary to complete the Annual Financial Filings and expects to file them by August 29, 2025. The Company will provide updates as further information regarding the Annual Financial Filings becomes available. Until the Annual Financial Filings are completed, the MCTO will remain in effect. The Company will continue to issue bi-weekly default status reports in accordance with National Policy 12-203 - Management Cease Trade Orders and intends to comply with the Alternative Information Guidelines for as long as it remains in default of the filing requirements. The Company confirms that, as of the date of this news release, there have been no material business developments or other material information regarding its affairs that have not been generally disclosed. On behalf of the Board Rodrigo Gallardo Interim CEO For more information contact: +52 (55) 6387-2293 [email protected] Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: Certain information contained in this press release constitutes forward-looking information or forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.'s expectations in respect of its ability to successfully execute its business plan or business model; statements, projections and estimates with respect to the Consolidation, the timing of the Consolidation and the Consolidation ratio, statements with respect to the filing of the Annual Financial Filings, the expectation that the Annual Financial Filings will be filed by the Filing Deadline, the expected number of issued and outstanding common shares on a post-Consolidation basis, the mailing of letters of transmittal, Xebra's ability to provide economic, environmental, social, or any benefits of any type, in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Canada, or elsewhere, including cannabis authorizations from the Mexican Health Regulatory Agency (COFEPRIS) and the timing of such permits or authorizations; its ability to successfully apply for and obtain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to commercialize, cultivate, grow, or process hemp or cannabis in Mexico, Canada, or elsewhere and related plans and timing; its ability to manufacture, commercialize or sell cannabis-infused beverages, wellness products, or other products in Mexico, Canada, or elsewhere, and its related plans and claims, including market interest and availability; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; financial projections including expected revenues, gross profits, and EBITDA (which is a non-GAAP financial measure); plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management's expectations, beliefs and assumptions in general, including manufacturing costs, production activity and market potential in Mexico or any jurisdiction; events or developments that XEBRA expects to take place in the future; general economic conditions; and other risk factors described in the prospectus of the Company dated September 30, 2021. All statements, other than statements of historical facts, are forward-looking information and statements. The words 'aim', 'believe', 'expect', 'anticipate', 'contemplate', 'target', 'intends', 'continue', 'plans', 'budget', 'estimate', 'may', 'will', and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by XEBRA as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability to complete the audit on the Annual Filings due to a requirement for additional funds, the inability of XEBRA to generate sufficient revenues or to raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete a potential acquisition for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; and the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approval for license applications. In addition, there is no assurance Xebra will: be a low-cost producer or exporter; obtain a dominant market position in any jurisdiction; have products that will be unique. The foregoing list is not exhaustive and XEBRA undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect XEBRA's actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, XEBRA. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements. SOURCE: Xebra Brands Ltd press release
